AstraZeneca (AZN)

Sector:

Pharma and Biotech

Index:

FTSE 100

10,046.00p
   
  • Change Today:
      77.00p
  • 52 Week High: 13,276.00
  • 52 Week Low: 9,501.00
  • Currency: UK Pounds
  • Shares Issued: 1,550.30m
  • Volume: 1,688,259
  • Market Cap: £155,744m
  • RiskGrade: 123
  • Beta: 0.87

AstraZeneca Overview

A world-leading pharmaceutical group, AstraZeneca was created in 1999 via the merger of Sweden's Astra and the UK's Zeneca, which had been demerged from chemicals group ICI in 1993. About half of its total sales are generated from the US, with over a third of revenues coming from its gastrointestinal treatments such as Prilosec (Losec) and Nexium.
Registrars: Equiniti
Brands: Losec, Prilosec, Nexium, Crestor

Key Personnel

Senior Independent Non-Executive Director: Philip A J Broadley
CEO and Executive director: Pascal Soriot
CFO & Executive Director: Aradhana Sarin
Chairman: Michel Demare
Independent Non-Executive Director: Euan Ashley
Independent Non-Executive Director: Deborah DiSanzo
Independent Non-Executive Director: Diana Layfield
Independent Non-Executive Director: Tony Mok
Independent Non-Executive Director: Nazneen Rahman
Independent Non-Executive Director: Sheri McCoy
Non-Executive Dir: Andreas Rummelt, Anna Manz, Marcus Wallenberg

Contact Details

Address: 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge,United Kingdom, CB2 0AA
Phone: +44 (0)20 3749 5000
Fax: +44 (0)20 7604 8151
Website: http://www.astrazeneca.com

Listings

Sector: Pharma and Biotech(LSE)
Index: FTSE 100, FTSE 350, FTSE All-Share
Overseas Listings: BATSLON:AZNL
ISIN: GB0009895292

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

AstraZeneca Market Data

Currency UK Pounds
Share Price 10,046.00p
Change Today 77.00p
% Change 0.77 %
52 Week High 13,276.00
52 Week Low 9,501.00
Volume 1,688,259
Shares Issued 1,550.30m
Market Cap £155,744m
Beta 0.87
RiskGrade 123

AstraZeneca Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
87.66% below the market average87.66% below the market average87.66% below the market average87.66% below the market average87.66% below the market average
88% below the sector average88% below the sector average88% below the sector average88% below the sector average88% below the sector average
Price Trend
27.11% below the market average27.11% below the market average27.11% below the market average27.11% below the market average27.11% below the market average
34.69% above the sector average34.69% above the sector average34.69% above the sector average34.69% above the sector average34.69% above the sector average
Income
78.05% below the market average78.05% below the market average78.05% below the market average78.05% below the market average78.05% below the market average
42.86% below the sector average42.86% below the sector average42.86% below the sector average42.86% below the sector average42.86% below the sector average
Growth
88.44% above the market average88.44% above the market average88.44% above the market average88.44% above the market average88.44% above the market average
94.12% above the sector average94.12% above the sector average94.12% above the sector average94.12% above the sector average94.12% above the sector average

What The Brokers Say

Strong Buy 9
Buy 15
Neutral 5
Sell 0
Strong Sell 1
Total 30
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

AstraZeneca Dividends

  Latest Previous
  1st Interim 2nd Interim
Ex-Div 08-Aug-24 22-Feb-24
Paid 09-Sep-24 25-Mar-24
Amount 100.00¢ 197.00¢

Trades for 21-Nov-2024

Time Volume / Share Price
16:08 10 @ 10,047.56p
16:08 5 @ 10,047.30p
16:08 79 @ 10,046.00p
16:08 390 @ 10,046.00p
16:08 137 @ 10,046.00p

AstraZeneca Key Personnel

Chair Michel Demare

Top of Page